

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A method for treating schizophrenia ~~a neurological disorder~~ in a subject suffering therefrom, the method comprising administering to the subject an effective amount of a SLURP-1 polypeptide comprising the amino acid sequence of SEQ ID NO: 2, thereby treating schizophrenia in the subject ~~to a subject suffering from said neurological disorder~~.
2. (Currently amended) The method of claim 1, wherein schizophrenia ~~a neurological disorder~~ comprises a pathology caused by dysfunction of an acetylcholine receptor selected from the group consisting of an alpha 7 nicotinic acetylcholine receptor and an alpha 7 nicotinic acetylcholine receptor related protein.
- 3-5. (Canceled).
6. (Currently amended) The method of claim 1, wherein the effective amount of the SLURP-1 polypeptide is from about 1.0 pM to about 10 µM.
7. (Currently amended) The method of claim 1, wherein the effective amount of the SLURP-1 polypeptide is administered to the subject by a method selected from the group consisting of orally, intravenously, intraperitoneally, intranasally, and intramuscularly.
8. (Canceled).
9. (Currently amended). A method for treating schizophrenia in a subject suffering therefrom, the method comprising administering to the subject an effective amount of a SLURP-1 polypeptide comprising amino acids 23-103 of the amino acid sequence of SEQ ID NO: 2, thereby treating schizophrenia in the subject ~~The method of claim 1, wherein the SLURP-1 is in a mature form~~.
10. (Currently amended). The method of claim 9, ~~wherein the mature form of SLURP-1 comprises~~ comprising administering to the subject an effective amount of a SLURP-1 polypeptide consisting of amino acids 23-103 of SEQ ID NO: 2 ~~SLURP-1~~.
11. (Original). The method of claim 1, wherein the subject is a mammal.
12. (Original). The method of claim 11, wherein the mammal is a human.

13-59. (Canceled).

60. (Currently amended). A method of treating schizophrenia ~~a neurological disorder~~ caused by the dysfunction of the alpha 7 nicotinic acetylcholine receptor in a subject suffering therefrom, the method comprising administering to the subject a composition comprising an effective amount of a peptide mimetic of the SLURP-1 polypeptide of SEQ ID NO: 2 and a carrier, wherein the composition modulates the function of an alpha 7 nicotinic acetylcholine receptor or of a related protein,

thereby treating schizophrenia in the subject ~~the composition of claim 58 to a subject suffering from said neurological disorder.~~

61-79. (Canceled).

80. (New). A method for treating schizophrenia in a subject suffering therefrom, the method comprising administering to the subject an effective amount of a SLURP-1 polypeptide at least 90% identical to the amino acid sequence of SEQ ID NO: 2, thereby treating schizophrenia in the subject.

81. (New). The method of claim 80, comprising administering to the subject an effective amount of a SLURP-1 polypeptide at least 95% identical to the amino acid sequence of SEQ ID NO: 2.

82. (New). The method of claim 80, comprising administering to the subject an effective amount of a SLURP-1 polypeptide at least 99% identical to the amino acid sequence of SEQ ID NO: 2.

83. (New). The method of claim 60, wherein the composition further comprises a SLURP-1 polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or a SLURP-1 polypeptide comprising amino acids 23-103 of the amino acid sequence of SEQ ID NO: 2.